- Products
THOROLD, ON, Feb. 12, 2019 /PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein stabilization and purification, today announced their unique cf-DNA/cf-RNA Preservative Tubes were found to be the most suitable for liquid biopsy when compared to other leading competitor's blood collection tubes (BCTs).
/PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider. Norgen's Propel Certification covers both the NextSeq 500 System and the NextSeq 550 System.
/PRNewswire/ - Diversigen Inc. (Houston, TX) and Norgen Biotek Corp. (Ontario, Canada) today announced that they have entered into a strategic partnership through which industry and academic researchers will benefit from comprehensive end-to-end logistical, sequencing, and analytical solutions to meet the growing needs for microbiome analyses.
/CNW/ - Norgen Biotek Corp., an innovative Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein purification and stabilization, today announced the recent launch of their new portfolio of product and service solutions for Next Generation Sequencing (NGS) applications. Norgen has extensive experience with NGS, and has leveraged this expertise to develop a number of new kits and workflows for NGS applications.
Copyright © 2020 Norgen Biotek Corp.